AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03471273 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: endoscopic management, surgery and follow up
Description: endoscopic management, surgery and follow up
Study NCT02079038 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Totalis
Study NCT02079038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Comparator Surgical Procedure
Study NCT03572452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: McKenzie Method
Description: Treatment according to the Mechanical Diagnosis and Therapy Approach
Study NCT03572452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice to saty active
Description: Physiotherapy councelling advicing to stay normally active
Study NCT00970918 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measurement of the Carotid Intima Media thickness
Description: one time, radiological procedure on both sides of the neck
Study NCT00970918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample testing for hs-CRP
Description: one time, blood sample taking
Study NCT01558947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy of ECX
Description: Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4\~6 weeks after surgery.
Study NCT01558947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-operative chemotherapy of XP
Description: Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2\~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4\~6 weeks after surgery.
Study NCT00006107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere
Study NCT00006107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT00006107 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02083692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT02152709 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 dose of 10µg/0.5ml hepatitis B vaccine
Description: 3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
Study NCT02152709 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 3 dose of 5µg/0.5ml hepatitis B vaccine
Description: 3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
Study NCT00808093 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK256073
Description: GSK256073 100 mg study drug
Study NCT01410513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR245409
Description: Pharmaceutical form:capsule Route of administration: oral
Study NCT00985465 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 1 or 2 doses
Study NCT02466763 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cochlear implant surgery
Description: Surgical placement of a cochlear implant device.
Study NCT01897363 — intervention group
Intervention type: OTHER
Intervention: Infants with Prader-Willi Syndrome
Description: Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
Study NCT01618669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Administered as an intravenous (IV) bolus
Study NCT01618669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regadenoson
Description: Administered as an intravenous (IV) bolus
Study NCT01618669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Study NCT01618669 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)
Study NCT01923207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DX-2930
Study NCT01923207 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo, subcutaneous administration
Study NCT04117204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables
Description: Fruits and Vegetable delivery, once a week for 12 weeks.
Study NCT02116881 — intervention group
Intervention type: PROCEDURE
Intervention: Colorectal Surgery
Description: Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
Study NCT04438694 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Convalescent Plasma
Study NCT04438694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of Care drugs administered as per Cairo University ICU protocol
Study NCT04438694 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care drugs administered as per Cairo University ICU protocol
Study NCT00700596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salvinorin A
Description: Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
Study NCT00700596 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control or Placebo SA (30 % ethanolic solution)
Study NCT01702558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at de-escalating doses (starting from 750 mg/m\^2) to determine the MTD.
Study NCT01525407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo myeloablative allogeneic PBSC transplant
Study NCT01702558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
Study NCT01702558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine will be administered at a dose of 3.6 mg/kg via IV infusion every 3 weeks.
Study NCT01702558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (T-DM1)
Description: Trastuzumab emtansine will be administered at a dose of 2.4 mg/kg via IV infusion every week.
Study NCT01702558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine will be administered at the MTD determined in Cohort 1.
Study NCT01702558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine will be administered at the MTD determined in Cohort 1.
Study NCT01525407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin Calcium
Description: Given PO
Study NCT01525407 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo myeloablative allogeneic PBSC transplant
Study NCT03815227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient birth
Description: Maternity out the same date or the next day of the birth and home-based follow up with a liberal midwife
Study NCT00929552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary oils (fish, vegetable oil)
Description: 6g pr day.
Study NCT03921034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
Study NCT03921034 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ropivacaine
Description: All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
Study NCT00929552 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary oils (fish, vegetable oil)
Description: 6g pr day.
Study NCT03921034 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: All patients will receive sedation with midazolam and/or fentanyl titrated to comfort during block procedures. Per our standard practice at Ochsner Medical Center, all patients will have either spinal or combined spinal-epidural anesthesia with mepivacaine 1.5% as the primary anesthetic during the surgery and sedation with propofol titrated to comfort. Also per our standard practice at Ochsner Medical Center, multimodal therapy will include ketamine 0.25mg/kg IV (up to 50mg) intraoperatively, dexamethasone 8mg IV intraoperatively, pregablin 150mg PO preoperatively (adjusted to 75mg for age over 70) followed by 75mg nightly (or home gabapentin dose), acetaminophen 1000mg IV followed by 100mg PO every 6 hours postoperatively, and celecoxib 400mg PO on POD #0 followed by 200mg PO daily.
Study NCT01954641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACCURE Navigator
Description: The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions.
Study NCT01954641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care by Cancer Center Care Team
Description: The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
Study NCT03742973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03742973 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT02999516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imaginary
Description: Participants imagine doing a motor task watching a video recording
Study NCT02233634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
Study NCT02233634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperventilation Breath-hold (HVBH)
Description: 1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
Study NCT02233634 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HVBH with Oxygen
Description: 1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
Study NCT02011100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carnosine
Study NCT02011100 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carnosine
Study NCT02028533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study NCT02028533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02999516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Motor imaginary
Description: Participants watch a television documentary
Study NCT02999516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tDCS
Description: transcranial direct current stimulation (tDCS) stimulation during 20 minutes in the motor cortex (bilaterally) at 1mA of intensity.
Study NCT02999516 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: tDCS sham
Description: tDCS stimulation during 30 seconds in the motor cortex (bilaterally) at 1mA of intensity and then 19 minutes and 30 seconds without any stimulation.
Study NCT02999516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: EEG monitoring of the cerebral cortex in real time with positive feedback in the computer screen when participants motor cortex is activated. The positive feedback consist in an object that moves to the top of the screen when activation occurs in the motor cortex. This task last during 20 minutes.
Study NCT02999516 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Neurofeedback sham
Description: EEG monitoring of the cerebral cortex in real time with randomized feedback in the computer screen despite motor cortex activation. The positive feedback consist in an object that moves to the top of the screen in a randomized time. This task last during 20 minutes.
Study NCT00620776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
Study NCT00620776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR
Description: Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
Study NCT00620776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine XR
Description: Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
Study NCT04000958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIRF measured by InCheck DIAL
Description: Peak inspiratory flow rates(PIFR) will be measured using the InCheck DIAL(Clement Clarke International Ltd, Harlow, UK and Alliance Tech Medical). The InCheck DIAL is accurate to +/- 10% or 10 L/min, whichever is greater, and can measure flows in the range of 15 to 120 L/min. Dry powder inhaler(DPI) is to be prescribed if PIFRr is over 60L/min, otherwise pressure metered dose inhaler(pMDI) with spacer is given. All the patients will be given inhaled corticosteroid（ICS）/long-acting β agonist（LABA）. For symptomatic patients, long-acting anticholinergic agents(LAMA) will also be used.
Study NCT04000958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular treament
Description: The choice of inhalers depends on physician's evaluation. The medication is the same as experimental group.
Study NCT02059226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioural therapy
Description: Internet-based CBT
Study NCT02059226 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-based resource page
Description: Static webpage
Study NCT03547310 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyoBeatz
Description: Training of the patient's muscle coordination, strength and ability to separately contract muscles, while holding up patient motivation. The patient is expected to follow a protocol of 4 weeks of training.
Study NCT02304523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0612
Description: Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Study NCT02304523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDFR0613
Description: Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Study NCT02304523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coolprep Powder
Description: Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
Study NCT02296567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
Study NCT02296567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
Study NCT02296567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
Study NCT02296567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
Study NCT02296567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
Study NCT02296567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
Study NCT02296567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
Study NCT02296567 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control group Subjects will no previous anti-VEGF treatment
Study NCT03116711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive CIQ plus High Carbohydrate Diet
Description: Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
Study NCT03116711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive CIQ plus High Protein Diet
Description: Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
Study NCT03116711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative CIQ plus High Carbohydrate Diet
Description: Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
Study NCT03116711 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Negative CIQ plus High Protein Diet
Description: Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
Study NCT00952458 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Description: Neuromonitoring of depth of sedation with Bispectral Index
Study NCT03391661 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education patient exercise
Description: Patients complete a 15 to 20-minute on-line exercise that inquires about 5 domains: the degree of central sensitization symptoms, catastrophizing and kinesiophobia, personality factors, stressors that triggered or exacerbated the pain, and adverse childhood experiences.
Study NCT03391661 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health behavior control intervention
Description: Patients engage in a 15 to 20-minute on-line exercise examining their health behaviors in five domains: exercise, sleep, diet, hygiene, and social connections.